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In Editorial on free radicals and cancer (1) it is postulated that many tumor 
cells are in pro-oxidant status that results either from increased production 
of oxygen free radicals or decreased expression of antioxidant enzymes. 
Possible protective and anticancer activities of antioxidant molecules by 
scavenging excess of free radicals are complex due to their potential interfer-
ences with redox regulation of some important physiological processes e.g. 
apoptosis. Modulation of the oxidant/anti-oxidant balance towards a more 
reduced state is likely to have control influence by limiting the survival and 
invasion of the most cancer cells. Therefore, the systemic administration 
of low molecular antioxidants could be helpful in the management of the 
systemic effects as well as for the side effects of therapy in breast cancer 
patients (2). Some possible protective effect of Vitamin E in cancer treatment 
have been found (3,4) but more specific effects are attributed to Vitamin E 
analogs, „mitocans,“ a novel group of anticancer agents (5).
Vitamin E analogue, alpha-tocopheryl succinate, suppresses malignant meso-
telioma in a preclinical model, alters cell cycle distribution sensitizing human 
osteosarcoma cells to methotrexate-induced apoptosis, promotes breast 
cancer tumor dormancy, and selectively induces apoptosis in neuroblastoma 
cells. Mechanisms of such alpha-tocopheryl succinate effects on tumor 
cells are under intensive investigation. Alpha-tocopheryl succinate-induced 
apoptosis may proceed through different mechanisms such as modulation 
of ERK1/2 and c-Jun N-terminal kinase in a biphasic manner (6), or by 
tocopherol-associated protein-1 (7). It seems that mitochondria play a central 
role in apoptosis induced by alpha-tocopheryl succinate indicating a role of 
reactive oxygen species (ROS) in apoptosis induction. Molecular mechanism 
of alpha-tocopheryl succinate-induced apoptosis in cancer cells emphasizes 
the multiple roles of reactive oxygen species and Bcl-2 family proteins. A role 
of nitric oxide and superoxide after alpha-tocopheryl succinate application in 
apoptotic and anticancer effects are also examined (8). These results, in some 
aspects, are opposite to those recently postulated (5) that it is essential for 
alpha-tocopheryl succinate to be redox-silent.
In this volume in a paper Alpha-tocopheryl succinate (α-TOS) influences cell 
vitality and enzyme activity in Ehrlich ascites carcinoma cells, by Karmen 
Stankov et al (9), a new original data are presented which may be useful 
in detection of molecular mechanism of alpha-tocopheryl succinate action. 
Authors investigated the in vivo effects of intraperitoneal application α-TOS on 
vitality of Ehrlich ascites carcinoma cells (EAC) (in mice), as well as the influ-
ence of α-TOS on specific activity of enzymes involved in antioxidative mecha-
nisms in EAC cells. The observed decrease in antioxidative potential (decrease 
in glutathione-dependent enzyme activity), may have the important influence 
on EAC cells increased susceptibility towards apoptosis, that was shown by 
decreased vitality of EAC cells after intraperitoneal application of α-TOS.
These changes in enzyme activity might be due to the alterations in gene 
expression, possibly induced by the α-TOS influence on ROS production or 
other signal transduction mechanisms. The vitamin E analogs inhibit prolif-
eration of cancer cells by several mechanisms including inhibition of DNA 
synthesis and by affecting the protein kinase C and the MAP kinase pathways. 
They are also able to efficiently induce the mechanisms of mitochondrial 
signal transmission (including ROS generation), which triggers apoptosis. 
Parallel existence of different mechanisms of action (redox and direct effects 
of the α-TOS) may be very important for effectiveness of some drugs used 
in clinical practice.
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